Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.

Kazmi F, Yerino P, McCoy C, Parkinson A, Buckley DB, Ogilvie BW.

Drug Metab Dispos. 2018 Aug;46(8):1066-1074. doi: 10.1124/dmd.118.081729. Epub 2018 May 7.

PMID:
29735754
3.

The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments.

Haupt LJ, Kazmi F, Ogilvie BW, Buckley DB, Smith BD, Leatherman S, Paris B, Parkinson O, Parkinson A.

Drug Metab Dispos. 2015 Nov;43(11):1744-50. doi: 10.1124/dmd.115.066597. Epub 2015 Sep 9.

4.

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.

Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P.

J Clin Pharmacol. 2015 Sep;55(9):1004-11. doi: 10.1002/jcph.507. Epub 2015 May 7.

PMID:
25851638
5.

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.

Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A.

Drug Metab Dispos. 2011 Nov;39(11):2020-33. doi: 10.1124/dmd.111.041293. Epub 2011 Jul 27.

6.

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, Ogilvie BW.

Drug Metab Dispos. 2011 Aug;39(8):1370-87. doi: 10.1124/dmd.111.038596. Epub 2011 Apr 27.

7.

Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments.

Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K, Kondo T, Nakayama H, Horita S, Ogilvie BW, Parkinson A, Hu Z, Sugiyama Y.

Drug Metab Dispos. 2011 Jun;39(6):1031-8. doi: 10.1124/dmd.110.036129. Epub 2011 Mar 7.

9.

Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.

Hirouchi M, Kusuhara H, Onuki R, Ogilvie BW, Parkinson A, Sugiyama Y.

Drug Metab Dispos. 2009 Oct;37(10):2103-11. doi: 10.1124/dmd.109.027193. Epub 2009 Jul 23.

10.

In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A.

Drug Metab Dispos. 2009 Oct;37(10):2045-54. doi: 10.1124/dmd.109.028274. Epub 2009 Jul 16.

11.

An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.

Nassar AE, King I, Paris BL, Haupt L, Ndikum-Moffor F, Campbell R, Usuki E, Skibbe J, Brobst D, Ogilvie BW, Parkinson A.

Drug Metab Dispos. 2009 Sep;37(9):1922-30. doi: 10.1124/dmd.109.027516. Epub 2009 Jun 11.

13.

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.

Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A.

Drug Metab Dispos. 2006 Jan;34(1):191-7. Epub 2005 Nov 18.

14.

The many books of nature: Renaissance naturalists and information overload.

Ogilvie BW.

J Hist Ideas. 2003 Jan;64(1):29-40. No abstract available.

PMID:
12841171

Supplemental Content

Loading ...
Support Center